CalciMedica Resolves Nasdaq MVLS Deficiency; Bid Price Compliance Still Pending
CALC is trading near its 52-week low of $2 (10% above the low).
Summary
CalciMedica resolved its Nasdaq market value deficiency via the alternative equity standard, but the minimum bid price issue remains unresolved with a September 14 deadline.
Key Events · Legal and Risk Events · CALC
-
MVLS Deficiency Closed
Nasdaq Staff determined CalciMedica complies with the alternative minimum stockholders' equity requirement (Rule 5550(b)(1)) based on Q2 2026 equity of $5,513,000, closing the market value of listed securities non-compliance notice.
-
Minimum Bid Price Still Unresolved
The company has not regained compliance with the $1.00 minimum bid price rule and has until September 14, 2026 to do so; the one-for-five reverse split implemented August 28, 2026 was intended to address this.
-
Reverse Split Implemented
The one-for-five reverse stock split became effective at 5:00 p.m. ET on August 28, 2026, reducing outstanding share count and proportionally increasing the share price.
-
Listing Risk Remains
There can be no assurance the company will regain bid price compliance or maintain other listing requirements, leaving Nasdaq delisting risk open.
Analysis · CALC · Life Sciences
CalciMedica cleared one Nasdaq listing hurdle after the Staff accepted its stockholders' equity of $5.5 million as satisfying the alternative minimum equity requirement, closing the market value of listed securities (MVLS) deficiency. However, the company still has not regained compliance with the $1.00 minimum bid price rule and faces a September 14, 2026 deadline. The recently implemented one-for-five reverse split was designed to lift the share price above $1.00, but there is no assurance it will succeed. With only $18.6 million in cash and a going concern warning from the Q2 10-Q, maintaining the Nasdaq listing is critical for access to capital.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CALC was trading at $2.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.7M. The 52-week trading range was $2.00 to $36.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.